Semaglutide vs Tesamorelin

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Semaglutide vs Tesamorelin: Semaglutide has the stronger overall evidence (8.5 vs 5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Semaglutide Edges Ahead

Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Semaglutide2 wins

Tesamorelin0 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Sgl8.5

Semaglutide

Too few graded studiesLimited safety

Tes5.0

Tesamorelin

Too few graded studiesLimited safety

Evidence

Evidence Score

Best8.5/10

Studies: 455

Meta-analyses: 134

Level: Very Strong

Evidence Score

5/10

Studies: 30

Meta-analyses: 2

Level: Moderate

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies197
Weight managementToo few graded studies182
Cardiovascular outcomesToo few graded studies58

Verdict

Too few graded studies

Top outcomes

Visceral fat & body compositionToo few graded studies14
Liver healthToo few graded studies7
Cognitive functionToo few graded studies3

Shared outcomes (1)

Outcomes where both Semaglutide and Tesamorelin have evidence — compare verdict strength side-by-side.

Visceral fat & body compositionToo few graded studies182Too few graded studies14

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.
Post-marketing reports of ileus (severely slowed gut motility).
May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly injection (Ozempic / Wegovy)

Recommended Dosage:

Approved regimen (Egrifta, HIV-associated lipodystrophy only): 2 mg once daily by subcutaneous injection. This is a prescription drug — the dose, indication and monitoring are set by a prescriber. The cognition RCT used a lower 1 mg/day. There is NO validated dose for off-label 'anti-aging' or physique use, and any such use is outside the evidence base.

Warnings

Tesamorelin is a PRESCRIPTION DRUG (Egrifta), NOT a dietary supplement — it should only be obtained and used under a prescription.
Approved ONLY to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. The popular off-label 'anti-aging' / bodybuilding use is NOT what the phase-3 trials studied, and benefit in non-HIV/healthy users is unproven.
It raises IGF-1: theoretical neoplasia/proliferation concern, and it is contraindicated in active malignancy.
Injection-site reactions are common; glucose/insulin can be affected (GH reduces insulin sensitivity) — monitoring is required.
The benefit is entirely treatment-dependent: visceral fat reaccumulates within months of stopping, so there is no durable drug-free effect.
Grey-market 'research-use-only' tesamorelin vials are unregulated — identity, purity, dose and sterility are unverified — and using them is off-label and outside the evidence base.
Contraindicated in pregnancy and in disruption of the hypothalamic-pituitary axis (per the approved label).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Egrifta / Egrifta SV (prescription, via a clinician)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Limited safetyTie

Drug Interactions:

Insulin / glucose-lowering drugs (moderate)
Corticosteroids / cortisone-replacement (moderate)
Drugs metabolized by CYP3A (e.g. some statins, certain antiretrovirals) (moderate)

Side Effects:

Injection-site reactions (erythema, pruritus, pain, irritation, swelling, bruising)Arthralgia / joint pain, myalgia, peripheral edema (GH-excess type effects)Increased fasting glucose / reduced insulin sensitivity

Contraindications:

Active malignancy — tesamorelin raises IGF-1, a theoretical proliferative/neoplasia concern; it is contraindicated in active cancer
Pregnancy — contraindicated; GH/IGF-1 stimulation is inappropriate in pregnancy

Shared goals

Manage weightSemaglutide

Semaglutide88/100

Tesamorelin58/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Substantial weight losspositive

Months (titrated over 16-20 weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

🔥 Visceral fat reduction (phase-3 RCTs, HIV lipodystrophy)positive

26-52 weeks

🫁 Liver fat reduction (RCTs in HIV-associated NAFLD)positive

6-12 months

🔄 Benefit reverses on discontinuation (trade-off)trade-off

Within months of stopping

🧠 Cognition: mixed, unapprovedneutral

20-24 weeks

Key studies

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).

N Engl J Med (2021) · Rct · n=1961

Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).

N Engl J Med (2023) · Rct · n=17604

Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).

N Engl J Med (2016) · Rct · n=3297

Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks

All Semaglutide studies

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

J Clin Endocrinol Metab (2010) · Rct · n=806

Pooled analysis of two multicenter, double-blind, placebo-controlled phase-3 RCTs (n=806 ART-treated HIV patients with excess abdominal fat), randomized 2:1 to tesamorelin 2 mg or placebo subcutaneously daily

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

J Acquir Immune Defic Syndr (2010) · Rct · n=404

12-month phase-3 RCT in 404 ART-treated HIV patients with excess abdominal fat; randomized 2:1 to tesamorelin 2 mg sc daily or placebo, then rerandomized at 6 months

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

AIDS (2008) · Rct · n=410

26-week safety-extension RCT (n=410) of the phase-3 program; tesamorelin 2 mg vs placebo subcutaneously daily, with rerandomization at week 26

All Tesamorelin studies

Frequently asked questions

Is Semaglutide better than Tesamorelin?

Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.

Is Semaglutide or Tesamorelin better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 58).

Can I take Semaglutide and Tesamorelin together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Semaglutide vs Tirzepatide Liraglutide vs Semaglutide AREDS2 Formula vs Semaglutide Dulaglutide vs Semaglutide Iron vs Tesamorelin Tesamorelin vs Whey Protein

Still deciding between Semaglutide and Tesamorelin?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Semaglutide details Tesamorelin details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.

Post-marketing reports of ileus (severely slowed gut motility).

May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Warnings

Tesamorelin is a PRESCRIPTION DRUG (Egrifta), NOT a dietary supplement — it should only be obtained and used under a prescription.

Approved ONLY to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. The popular off-label 'anti-aging' / bodybuilding use is NOT what the phase-3 trials studied, and benefit in non-HIV/healthy users is unproven.

It raises IGF-1: theoretical neoplasia/proliferation concern, and it is contraindicated in active malignancy.

Injection-site reactions are common; glucose/insulin can be affected (GH reduces insulin sensitivity) — monitoring is required.

The benefit is entirely treatment-dependent: visceral fat reaccumulates within months of stopping, so there is no durable drug-free effect.

Grey-market 'research-use-only' tesamorelin vials are unregulated — identity, purity, dose and sterility are unverified — and using them is off-label and outside the evidence base.

Contraindicated in pregnancy and in disruption of the hypothalamic-pituitary axis (per the approved label).

Frequently asked questions

Is Semaglutide better than Tesamorelin?

Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.

Is Semaglutide or Tesamorelin better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 58).

Can I take Semaglutide and Tesamorelin together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.